ADICON Holdings (09860) has unveiled its interim results for the six months ended June 30, 2026, showcasing a resilient financial performance amidst evolving market conditions. The group generated revenue of RMB 1.285 billion, marking a year-on-year increase of 1.12%, while profit attributable to owners of the parent company climbed by 17.35% to RMB 32.006 million. Earnings per share stood at RMB 0.04 for the period.

The company attributed the revenue growth primarily to improved sales volumes. Although pricing pressures linked to medical insurance reimbursement remain, they are gradually easing, and the combined effect of these factors drove a rebound in overall revenue during the first half of the year. Management noted that industry conditions have shown continuous signs of improvement since the start of the year.

Business volume expansion was fueled by sustained investments in the group's specialized testing, co-built laboratory, and CRO operations. Additionally, the sales team's persistent efforts in acquiring new clients contributed significantly to the growth trajectory during the reporting period.